Jump to content

Sudden cardiac death of athletes

From Wikipedia, the free encyclopedia
(Redirected from Sudden death of athletes)
Defibrillator training kit

It remains a difficult medical challenge to prevent the sudden cardiac death of athletes, typically defined as natural, unexpected death from cardiac arrest within one hour of the onset of collapse symptoms, excluding additional time on mechanical life support.[1] (Wider definitions of sudden death are also in use, but not usually applied to the athletic situation.) Most causes relate to congenital or acquired cardiovascular disease with no symptoms noted before the fatal event. The prevalence of any single, associated condition is low, probably less than 0.3% of the population in the athletes' age group,[citation needed] and the sensitivity and specificity of common screening tests leave much to be desired. The single most important predictor is fainting or near-fainting during exercise, which should require detailed explanation and investigation.[2] The victims include many well-known names, especially in professional association football, and close relatives are often at risk for similar cardiac problems.

Causes

[edit]

The sudden cardiac deaths of 387 young American athletes (under age 35) were analyzed in a 2003 medical review:[3]

Cause Incidence
Hypertrophic cardiomyopathy 26% Genetically determined
Commotio cordis 20% Structurally normal heart, disrupted electrically by a blow to the chest
Coronary artery anomalies 14% Exact mechanisms unknown; some association with other congenital CVS abnormalities
Left ventricular hypertrophy of undetermined origin 7% Probable variant of hypertrophic cardiomyopathy
Myocarditis 5% Acute inflammation
Ruptured aortic aneurysm (Marfan syndrome) 3% Genetically determined; also associated with unusual height
Arrhythmogenic right ventricular cardiomyopathy 3% Genetically determined
Tunneled coronary artery 3% Congenital abnormality
Aortic valve stenosis 3% Multiple causes
Atherosclerotic coronary artery disease 3% Mainly acquired; dominant cause in older adults
Other diagnosis 13%

While most causes of sudden cardiac death relate to congenital or acquired cardiovascular disease, an exception is commotio cordis, in which the heart is structurally normal but a potentially fatal loss of rhythm occurs because of the accident of timing of a blow to the chest. Its fatality rate is about 65% even with prompt CPR and defibrillation, and more than 80% without.[4][5]

Age 35 serves as an approximate borderline for the likely cause of sudden cardiac death. Before age 35, congenital abnormalities of the heart and blood vessels predominate. These are usually asymptomatic prior to the fatal event, although not invariably so.[6] Congenital cardiovascular deaths are reported to occur disproportionately in African-American athletes.[7]

After age 35, acquired coronary artery disease predominates (80%),[6] and this is true regardless of the athlete's former level of fitness.[citation needed]

Various performance-enhancing drugs can increase cardiac risk, though evidence has been inconclusive about their involvement in sudden cardiac deaths.[8]

Genetics

[edit]

Cardiomyopathies

[edit]
Arrhythmogenic right ventricular dysplasia, showing fatty infiltration of right and left ventricle, and poor contraction of right ventricle

Cardiomyopathies are generally inherited as autosomal dominants, although recessive forms have been described, and dilated cardiomyopathy can also be inherited in an X-linked pattern. Consequently, in addition to tragedy involving an athlete who succumbs, there are medical implications for close relatives. Among family members of index cases, more than 300 causative mutations have been identified. However, not all mutations have the same potential for severe outcomes, and there is not yet a clear understanding of how these mutations (which affect the same myosin protein molecule) can lead to the dramatically different clinical characteristics and outcomes associated with hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM).[9]

Since HCM, as an example, is typically an autosomal dominant trait, each child of an HCM parent has a 50% chance of inheriting the mutation. In individuals without a family history, the most common cause of the disease is a "de novo" mutation of the gene that produces the β-myosin heavy chain.[citation needed]

Channelopathies

[edit]

Sudden cardiac death can usually be attributed to cardiovascular disease or commotio cordis, but about 20% of cases show no obvious cause and remain undiagnosed after autopsy. Interest in these "autopsy-negative" deaths has centered around the "ion channelopathies". These electrolyte channels are pores regulating the movement of sodium, potassium and calcium ions into cardiac cells, collectively responsible for creating and controlling the electrical signals that govern the heart's rhythm. Abnormalities in this system occur in relatively rare genetic diseases such as Long QT syndrome, Brugada syndrome, and Catecholaminergic polymorphic ventricular tachycardia, all associated with sudden death. Consequently, autopsy-negative sudden cardiac deaths (no physical abnormalities identified) may comprise a larger part of the channelopathies than previously anticipated.[10][11]

Heritable connective tissue diseases

[edit]
Myxomatous degeneration of the aortic valve, common in Marfan syndrome

Heritable connective tissue diseases are rare, each disorder estimated at one to ten per 100,000, of which Marfan syndrome is the most common. It is carried by the FBN1 gene on chromosome 15, which encodes the connective protein fibrillin-1,[12][13] inherited as a dominant trait. This protein is essential for synthesis and maintenance of elastic fibers. Since these fibers are particularly abundant in the aorta, ligaments, and the ciliary zonules of the eye, these areas are among the worst affected. Everyone has a pair of FBN1 genes and, because transmission is dominant, those who have inherited one affected FBN1 gene from either parent will have Marfan syndrome. Although it is most frequently inherited as an autosomal dominant, there is no family history in 25% of cases.[14]

Recruiting practices aimed at attracting athletes who are unusually tall or who have an unusually wide arm span (characteristics of Marfan syndrome) can increase the prevalence of the syndrome within sports such as basketball and volleyball.[15]

DNA testing

[edit]

After a disease-causing mutation has been identified in an index case (which is not always accomplished conclusively), the main task is genetic identification of carriers within a pedigree, a sequential process known as "cascade testing". Family members with the same mutation may show different severities of disease, a phenomenon known as "variable penetrance". As a result, some may remain asymptomatic, with little lifelong evidence of disease. Nevertheless, their children remain at risk of inheriting the disorder and potentially being more severely affected.[16]

Screening

[edit]
See also: Hypertrophic cardiomyopathy screening
Echocardiogram showing left ventricle

Screening athletes for cardiac disease can be problematic because of low prevalence and inconclusive performance of various tests that have been used. Nevertheless, sudden death among seemingly healthy individuals attracts much public and legislator attention because of its visible and tragic nature.[17]

As an example, the Texas Legislature appropriated US$1 million for a pilot study of statewide athlete screening in 2007. The study employed a combination of questionnaire, examination and electrocardiography for 2,506 student athletes, followed by echocardiography for 2,051 of them, including any students with abnormal findings from the first three steps. The questionnaire alone flagged 35% of the students as potentially at risk, but there were many false positive results, with actual disease being confirmed in less than 2%. Further, a substantial number of screen-positive students declined repeated recommendations for follow-up evaluation. (Individuals who are conclusively diagnosed with cardiac disease are usually told to avoid competitive sports.) It should be stressed that this was a single pilot program, but it was indicative of the problems associated with large-scale screening, and consistent with experience in other locations with low prevalence of sudden death in athletes.[18]

Incidence

[edit]

Sudden cardiac death occurs in approximately one per 200,000 young athletes per year, usually triggered during competition or practice.[6] The victim is usually male and associated with association football, basketball, ice hockey, or American football, reflecting the large number of athletes participating in these sustained and strenuous sports.[3] For a normally healthy age group, the risk appears to be particularly magnified in competitive basketball, with sudden cardiac death rates as high as one per 3,000 annually for male basketball players in NCAA Division I.[19] This is still far below the rate for the general population, estimated as one per 1,300–1,600 and dominated by the elderly.[20] However, a population as large as the United States will experience the sudden cardiac death of a competitive athlete at the average rate of one every three days, often with significant local media coverage heightening public attention.[17]

In the United States approximately 8 to 10 deaths per year can be attributed to sudden cardiac death in NCAA with overall rate of 1 per 43,000.[21][22]

Notable cases

[edit]
This is a dynamic list and may never be able to satisfy particular standards for completeness. You can help by adding missing items with reliable sources.

These athletes, with notable careers, experienced sudden cardiac death by age 40.

See also

[edit]

References

[edit]
  1. ^ van der Werf C, van Langen IM, Wilde AA (February 2010). "Sudden death in the young: what do we know about it and how to prevent?". Circ Arrhythmia Electrophysiol. 3 (1): 96–104. doi:10.1161/CIRCEP.109.877142. PMID 20160177.
  2. ^ Hastings JL, Levine BD (March 2012). "Syncope in the athletic patient". Prog Cardiovasc Dis. 54 (5): 438–44. doi:10.1016/j.pcad.2012.02.003. PMID 22386295.
  3. ^ a b Maron, Barry J. (September 11, 2003). "Sudden Death in Young Athletes". New England Journal of Medicine. 349 (11): 1064–1075. doi:10.1056/NEJMra022783. PMID 12968091. S2CID 6487670.
  4. ^ Maron, BJ; Estes, NAM III (March 2010). "Commotio cordis". New England Journal of Medicine. 362 (10): 917–927. doi:10.1056/NEJMra0910111. PMID 20220186.
  5. ^ "Position Statement on Commotio Cordis". US Lacrosse. January 2008. Retrieved 22 February 2017.
  6. ^ a b c Ferreira M, Santos-Silva PR, de Abreu LC, Valenti VE, Crispim V, Imaizumi C, Filho CF, Murad N, Meneghini A, Riera AR, de Carvalho TD, Vanderlei LC, Valenti EE, Cisternas JR, Moura Filho OF, Ferreira C (Aug 3, 2010). "Sudden cardiac death athletes: a systematic review". Sports Med Arthrosc Rehabil Ther Technol. 2: 19. doi:10.1186/1758-2555-2-19. PMC 2923123. PMID 20682064.
  7. ^ Maron BJ, Carney KP, Lever HM, Lewis JF, Barac I, Casey SA, Sherrid MV (March 2003). "Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy". Journal of the American College of Cardiology. 41 (6): 974–980. doi:10.1016/S0735-1097(02)02976-5. PMID 12651044.
  8. ^ La Gerche, André; Brosnan, Maria J. (January 3, 2017). "Cardiovascular Effects of Performance-Enhancing Drugs". Circulation. 135 (1): 89–99. doi:10.1161/CIRCULATIONAHA.116.022535. PMID 28028062.
  9. ^ Moore JR, Leinwand L, Warshaw DM (Jul 20, 2012). "Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor". Circ Res. 111 (3): 375–85. doi:10.1161/CIRCRESAHA.110.223842. PMC 3947556. PMID 22821910.
  10. ^ Westfal RE, Reissman S, Doering G (Jul 1996). "Out-of-hospital cardiac arrests: an 8-year New York City experience". Am J Emerg Med. 14 (4): 364–8. doi:10.1016/S0735-6757(96)90050-9. PMID 8768156.
  11. ^ de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, van Ree JW, Daemen MJ, Houben LG, Wellens HJ (Nov 1997). "Out-of-hospital cardiac arrest in the 1990s: a population-based study in the Maastricht area on incidence, characteristics and survival". J Am Coll Cardiol. 30 (6): 1500–5. doi:10.1016/s0735-1097(97)00355-0. PMID 9362408.
  12. ^ Kainulainen K, Karttunen L, Puhakka L, Sakai L, Peltonen L (January 1994). "Mutations in the fibrillin gene responsible for dominant ectopia lentis and neonatal Marfan syndrome". Nat. Genet. 6 (1): 64–9. doi:10.1038/ng0194-64. PMID 8136837. S2CID 21910482.
  13. ^ Dietz HC, Loeys B, Carta L, Ramirez F (November 2005). "Recent progress towards a molecular understanding of Marfan syndrome". Am J Med Genet C Semin Med Genet. 139C (1): 4–9. doi:10.1002/ajmg.c.30068. PMID 16273535. S2CID 25825152.
  14. ^ Armon K, Bale P (June 2012). "Identifying heritable connective tissue disorders in childhood". Practitioner. 256 (1752): 19–23, 2–3. PMID 22916581.
  15. ^ Demak, Richard (February 17, 1986). "Marfan Syndrome: A Silent Killer". Sports Illustrated. Retrieved February 12, 2021.
  16. ^ Raju H, Alberg C, Sagoo GS, Burton H, Behr ER (Nov 21, 2011). "Inherited cardiomyopathies" (PDF). BMJ. 343: d6966. doi:10.1136/bmj.d6966. PMID 22106372. S2CID 35135113.
  17. ^ a b Link, MS; Estes, NAM III (May 2012). "Sudden Cardiac Death in the Athlete". Circulation. 125 (20): 2511–2516. doi:10.1161/CIRCULATIONAHA.111.023861. PMID 22615422.
  18. ^ Zeltser I, Cannon B, Silvana L, Fenrich A, George J, Schleifer J, Garcia M, Barnes A, Rivenes S, Patt H, Rodgers G, Scott W (Jun 15, 2012). "Lessons learned from preparticipation cardiovascular screening in a state funded program". Am J Cardiol. 110 (6): 902–8. doi:10.1016/j.amjcard.2012.05.018. PMID 22704711.
  19. ^ Harmon KG, Asif IM, Klossner D, Drezner JA (April 2011). "Incidence of sudden cardiac death in National Collegiate Athletic Association athletes". Circulation. 123 (15): 1594–1600. doi:10.1161/CIRCULATIONAHA.110.004622. PMID 21464047.
  20. ^ Chugh SS, Reinier K, Teodorescu C, Evanado A, Kehr E, Al Samara M, Mariani R, Gunson K, Jui J (Nov–Dec 2008). "Epidemiology of sudden cardiac death: clinical and research implications". Prog Cardiovasc Dis. 51 (3): 213–28. doi:10.1016/j.pcad.2008.06.003. PMC 2621010. PMID 19026856. For the world (total population approx. 6,540,000,000), the estimated annual burden of sudden cardiac death would be in the range of 4–5 million cases per year.
  21. ^ Asif, Irfan M.; Harmon, Kimberly G. (2017-02-01). "Incidence and Etiology of Sudden Cardiac Death: New Updates for Athletic Departments". Sports Health. 9 (3): 268–279. doi:10.1177/1941738117694153. ISSN 1941-7381. PMC 5435153. PMID 28452637.
  22. ^ Harmon, Kimberly G.; Asif, Irfan M.; Maleszewski, Joseph J.; Owens, David S.; Prutkin, Jordan M.; Salerno, Jack C.; Zigman, Monica L.; Ellenbogen, Rachel; Rao, Ashwin; Ackerman, Michael J.; Drezner, Jonathan A. (2015-07-07). "Incidence, Etiology, and Comparative Frequency of Sudden Cardiac Death in NCAA Athletes: A Decade in Review". Circulation. 132 (1): 10–19. doi:10.1161/CIRCULATIONAHA.115.015431. ISSN 0009-7322. PMC 4496313. PMID 25977310.
Retrieved from "https://wiki.riteme.site/w/index.php?title=Sudden_cardiac_death_of_athletes&oldid=1258895961"